Adaptimmune Limited

About us

With a research base in Oxford, UK and a clinical base in Philadelphia, US, Adaptimmune is focused on the use of T cell therapy to treat cancer. It aims to utilise the body’s own machinery – the T cell – to target and destroy cancerous by using engineered, increased affinity T cell receptors (TCRs) as a means of strengthening natural patient T cell responses.

Contact us

Keep up-to-date with latest news, events and opportunities

Subscribe to our newsletter